The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
Jonathan R Carapetis - One of the best experts on this subject based on the ideXlab platform.
-
status of research and development of vaccines for Streptococcus pyogenes
Vaccine, 2016Co-Authors: Andrew C Steer, Jonathan R Carapetis, James B Dale, John D Fraser, Michael F Good, Luiza Guilherme, Nicole J Moreland, Kim E Mulholland, Florian Schodel, Pierre R SmeestersAbstract:Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.
-
Reply to "Susceptibility of Streptococcus pyogenes to trimethoprim-sulfamethoxazole".
Journal of Clinical Microbiology, 2013Co-Authors: Asha C. Bowen, Steven Y. C. Tong, Jonathan R CarapetisAbstract:We thank Gelfand et al. ([1][1]) for their interest in our article on the in vitro susceptibility of Streptococcus pyogenes to trimethoprim-sulfamethoxazole (SXT) ([2][2]). We agree that the two cases outlined by Gelfand et al. act as cautionary points for clinical practice, as there are currently
Pierre R Smeesters - One of the best experts on this subject based on the ideXlab platform.
-
status of research and development of vaccines for Streptococcus pyogenes
Vaccine, 2016Co-Authors: Andrew C Steer, Jonathan R Carapetis, James B Dale, John D Fraser, Michael F Good, Luiza Guilherme, Nicole J Moreland, Kim E Mulholland, Florian Schodel, Pierre R SmeestersAbstract:Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.
Magnus Rasmussen - One of the best experts on this subject based on the ideXlab platform.
-
Penicillin-resistant Streptococcus pyogenes?
Fems Microbiology Letters, 2011Co-Authors: Fredrik Kahn, Magnus RasmussenAbstract:Dear Editor, We read with interest the article ‘Epidemiological characterization of Streptococcus pyogenes isolated from patients with multiple onsets of pharyngitis’ by Ogawa et al . (2011). The authors address the important issue of recurrent …
-
Recurrent Sepsis Caused by Streptococcus pyogenes
Journal of Clinical Microbiology, 2011Co-Authors: Magnus RasmussenAbstract:I report that a 75-year-old man with severe atherosclerosis experienced two episodes of bacteremia with Streptococcus pyogenes of type emm87. Recurrent sepsis with S. pyogenes is extremely rare, and a foot ulcer was the suspected point of entry. The patient did not develop opsonizing antibodies to the isolate.
-
Proteolysis and its regulation at the surface of Streptococcus pyogenes
Molecular Microbiology, 2002Co-Authors: Magnus Rasmussen, Lars BjörckAbstract:Pathogenic bacteria often produce proteinases that are believed to be involved in virulence. Moreover, several host defence systems depend on proteolysis, demonstrating that proteolysis and its regulation play an important role during bacterial infections. Here, we discuss how proteolytical events are regulated at the surface of Streptococcus pyogenes during infection with this important human pathogen. Streptococcus pyogenes produces proteinases, and host proteinases are produced and released as a result of the infection. Streptococcus pyogenes also recruits host proteinase inhibitors to its surface, suggesting that proteolysis is tightly regulated at the bacterial surface. We propose that the initial phase of a S. pyogenes infection is characterized by inhibition of proteolysis and complement activity at the bacterial surface. This is achieved mainly through binding of host proteinase inhibitors and complement regulatory proteins to bacterial surface proteins. In a later phase of the infection, massive proteolytic activity will release bacterial surface proteins and degrade human tissues, thus facilitating bacterial spread. These proteolytic events are regulated both temporally and spatially, and should influence virulence and the outcome of S. pyogenes infections.
Andrew C Steer - One of the best experts on this subject based on the ideXlab platform.
-
status of research and development of vaccines for Streptococcus pyogenes
Vaccine, 2016Co-Authors: Andrew C Steer, Jonathan R Carapetis, James B Dale, John D Fraser, Michael F Good, Luiza Guilherme, Nicole J Moreland, Kim E Mulholland, Florian Schodel, Pierre R SmeestersAbstract:Streptococcus pyogenes is an important global pathogen, causing considerable morbidity and mortality, especially in low and middle income countries where rheumatic heart disease and invasive infections are common. There is a number of promising vaccine candidates, most notably those based on the M protein, the key virulence factor for the bacterium. Vaccines against Streptococcus pyogenes are considered as impeded vaccines because of a number of crucial barriers to development. Considerable effort is needed by key players to bring current vaccine candidates through phase III clinical trials and there is a clear need to develop a roadmap for future development of current and new candidates.
Yoshihiro Kikuchi - One of the best experts on this subject based on the ideXlab platform.
-
Case of severe Streptococcus pyogenes pneumonia with Streptococcus toxic shock syndrome
The journal of the Japanese Respiratory Society, 2008Co-Authors: Noriko Izumiyama, Hiroshi Miki, Yutaka Shishikura, Chiharu Kawaguchi, Wakana Saitou, Tadashi Kikuchi, Katsunori Kumagai, Kan Sasamori, Yoshihiro KikuchiAbstract:A 30-year-old woman who had until recently been healthy, was transferred to our hospital by ambulance with complaints of dyspnea and pain in both lower limbs. She had 1-week history of sore throat, fever and cough. She had been to a neighboring clinic three days previously, and had been prescribed some medication for bronchitis, but her symptoms had not improved. By the time of admission, she was already in shock and had severe respiratory failure. Laboratory data showed renal dysfunction, disseminated intravascular coagulation, CPK elevation and severe metabolic acidosis. Chest x-ray and CT films revealed consolidation of the entire right lung field. The patient was quickly intubated and we began mechanical ventilation. We immediately initiated broad-spectrum antibiotics, immunogloblin, dopamine hydrochloride and gabexate mesilate, but she died 7 hours later. From cultures of blood and sputum taken from the patient, Streptococcus pyogenes was isolated. On the basis of these clinical and bacteriological findings, we confirmed a diagnosis of pneumonia and toxic shock syndrome caused by Streptococcus pyogenes (STSS). Serologically her M protein was serotyped as M1, and with regard to Streptococcal pyrogenic exotoxin genes were identified as speA and speB. These serological findings were consistent with the most frequent type that causes STSS. In spite of the uncommon cause of community-acquired pneumonia, Streptococcus pyogenes can potentially affect healthy individuals. The pneumonia can be complicated with STSS and so the clinical course may be severe and fulminant. The evidence acquired from this case suggests that in the event of severe pneumonia with shock, we should be aware that this may represent the presence of Streptococcus pyogenes and/or toxic shock syndrome.
